Puxitatug Samrotecan for endometrial neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 30 Jun 2025: Trial registered, NCT07044336
  2. 1 Aug 2025: Trial started, NCT07044336

The trials

NCT05123482: A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

State
Under way
Phase
Phase 1 and Phase 2
People
460 planned
Started
18 Oct 2021
Primary completion
29 Sep 2027
Arms
Sub-Study 1 AZD8205 Monotherapy
Results
None posted
  1. 18 Oct 2021: Trial started
  2. 17 Nov 2021: Trial registered

NCT07044336: Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

State
Under way
Phase
Phase 3
People
800 planned
Started
1 Aug 2025
Primary completion
15 Oct 2027
Arms
Puxitatug Samrotecan
Results
None posted
  1. 30 Jun 2025: Trial registered
  2. 1 Aug 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.